AstraZeneca PLC and Daiichi Sankyo Co., Ltd. presented data on 8 and 9 September that seem to support their decision to seek US Food and Drug Administration approval for their TROP2-targeting antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd) as a second-line or later treatment for non-small cell lung cancer (NSCLC), but only in patients with non-squamous histology. The FDA is expected to make its approval decision by 20 December.
AstraZeneca/Daiichi Make Their Case For Dato-DXd In Non-Squamous Lung Cancer
Early-Stage PD-L1/Chemo Combo Data Also Reported
Data at WCLC showed why the TROP2-targeting ADC datopotamab deruxtecan is most effective in non-squamous NSCLC in second or later lines as presented in overall survival data at the meeting.
More from Clinical Trials
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
More from R&D
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
The UK giant is forecasting peak sales of $5bn plus
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.